Global Leading Market Research Publisher QYResearch announces the release of its latest report “AI in Biotechnology – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global AI in Biotechnology market, including market size, share, demand, industry development status, and forecasts for the next few years.
For biotech R&D executives, pharmaceutical chief scientific officers, and healthcare investors, the core challenge is no longer about if to adopt artificial intelligence, but how to integrate machine learning and deep learning into drug discovery, genomics, and diagnostics to reduce failure rates and accelerate time-to-market. AI in biotechnology directly addresses this need by combining computational power with biological research – analyzing complex biological data, automating experimental design, and optimizing processes across life sciences – enabling faster identification of drug candidates, more accurate disease diagnosis, and personalized treatment strategies.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5056958/ai-in-biotechnology
Market Sizing & Growth Trajectory (2024-2031)
According to QYResearch’s latest proprietary models, the global market for AI in Biotechnology was estimated to be worth US$ 1,033 million in 2024 and is forecast to reach a readjusted size of US$ 1,971 million by 2031, growing at a robust CAGR of 10.6% during the forecast period 2025-2031.
Executive Insight (Q1 2026 Update): Since Q3 2025, three major trends have accelerated AI adoption in biotech: (1) generative AI models for protein design (e.g., AlphaFold 3, ESMFold) have reduced early-stage drug discovery timelines by 40-60%; (2) the FDA’s Emerging Drug Safety Technology Program (2025) has fast-tracked 12 AI-discovered molecules into clinical trials; and (3) the EU’s AI Act (effective August 2026) has created regulatory clarity for AI-based diagnostic tools – key trends detailed in QYResearch’s full report.
Product Definition: The Computational Biology Revolution
Artificial Intelligence (AI) in biotechnology refers to the use of machine learning, deep learning, and other computational models to analyze complex biological data, automate experimental design, and optimize processes in life sciences. It integrates computational power with biological research to accelerate drug discovery, genomics, diagnostics, agriculture biotech, and industrial biotechnology.
Unlike traditional biotech R&D (which relies on hypothesis-driven experimentation, high-throughput screening, and iterative optimization), AI-powered biotech delivers:
- Accelerated target discovery (from 3-5 years to 6-12 months using generative models)
- Reduced failure rates (AI-optimized candidates have 30-40% higher Phase II success rates vs. industry average)
- In silico clinical trials (simulating patient responses before human trials)
- De novo protein design (generating novel enzymes, antibodies, and peptides)
- Multi-omics integration (combining genomics, proteomics, metabolomics, and clinical data)
Key Industry Characteristics & Strategic Segmentation
1. AI Technologies: Machine Learning/Deep Learning vs. NLP vs. Others
| Feature | ML & Deep Learning | Natural Language Processing (NLP) | Others (computer vision, robotics) |
|---|---|---|---|
| Primary Applications | Drug discovery, genomics, protein folding | Literature mining, clinical trial matching, real-world evidence | High-content screening, lab automation |
| Key Techniques | Neural networks, GNNs, transformers, reinforcement learning | BERT, BioBERT, GPT fine-tuned on PubMed | CNNs, reinforcement learning, computer vision |
| Market Share (2024) | 68% | 18% | 14% |
| CAGR (2025-2031) | 11.2% | 9.8% | 10.1% |
Source: QYResearch technology analysis, Q1 2026
Machine learning and deep learning dominate the market (68% share) and are the fastest-growing segment, driven by advances in generative models for protein design (AlphaFold 3, Chroma, ESMFold) and structure-based drug discovery. NLP is critical for extracting insights from the 35+ million biomedical publications and 400,000+ clinical trials, with fine-tuned language models (BioGPT, PubMedBERT) reducing literature review time by 70-80%.
2. Application Verticals: Drug Development vs. Disease Diagnosis vs. Others
- Drug Development (62% of 2024 revenue): Largest and fastest-growing segment (12.1% CAGR). Includes target discovery, lead optimization, ADMET prediction (absorption, distribution, metabolism, excretion, toxicity), and clinical trial optimization. Case Example (Q4 2025): Recursion Pharmaceuticals (partnered with Bayer) announced that AI-discovered lead compounds for fibrosis entered Phase I clinical trials in 18 months – 60% faster than industry average (45 months), at 40% lower cost.
- Disease Diagnosis and Treatment (28% of revenue): Strong growth (9.5% CAGR). Includes AI-powered medical imaging (radiology, pathology), genomics-based diagnostics (cancer subtyping, rare disease identification), and personalized treatment recommendations. Case Example (Q1 2026): Owkin’s AI model for breast cancer metastasis prediction (MOSAIC) received FDA Breakthrough Device designation, achieving 94% accuracy vs. 78% for standard pathology – reducing unnecessary chemotherapy by an estimated 35%.
- Other (10% of revenue): Includes agriculture biotech (crop yield prediction, gene editing optimization), industrial biotech (enzyme engineering, fermentation optimization), and synthetic biology (pathway design, strain engineering).
3. Technical Deep Dive: The Data Quality & Validation Challenge
The primary technical barrier for AI in biotechnology is data quality and standardization – biological data is heterogeneous, noisy, and often siloed across organizations. Key innovations (2025-2026) include:
- Federated learning: Owkin’s platform enables multiple institutions (hospitals, biotech companies) to train AI models on distributed data without sharing raw patient information, addressing privacy concerns (GDPR, HIPAA) and data silos. In 2025, a consortium of 15 European cancer centers used federated learning to develop a biomarker discovery model, achieving 20% higher accuracy than any single-institution model.
- Synthetic biological data generation: Generative models (e.g., variational autoencoders, GANs) can create realistic genomic, proteomic, and clinical datasets for training AI models where real data is scarce or expensive. XtalPi and Schrödinger use synthetic data to augment their drug discovery platforms, reducing experimental data requirements by 50-70%.
- Explainable AI (XAI) for regulatory approval: The FDA and EMA now require some level of model interpretability for AI-based diagnostics and drug discovery tools. Techniques such as SHAP (SHapley Additive exPlanations) and attention mechanisms allow researchers to identify which molecular features drove a prediction, increasing regulatory confidence. In 2025, the FDA issued draft guidance on “Prediction Model Validation for Drug Development,” explicitly recommending XAI approaches for high-risk decisions.
4. Policy & Regulatory Drivers (2025-2026)
- EU AI Act (effective August 1, 2026): Classifies AI in biotech as “high-risk” (Annex III), requiring conformity assessments, risk management systems, and technical documentation. However, the Act provides regulatory clarity, enabling AI biotech companies to plan compliance pathways. Estimated compliance cost: $500,000-2,000,000 per high-risk application.
- US FDA’s Emerging Drug Safety Technology Program (EDSTP) (2025): Fast-track designation for AI-discovered molecules. As of Q1 2026, 12 molecules have been accepted, with average review time reduced from 10 months to 4 months. Recipients include Recursion Pharmaceuticals (REC-994 for cerebral cavernous malformation) and Exscientia (EXS-21546 for immuno-oncology).
- China NMPA’s AI Medical Device Guidelines (2025 revision): Updated to include “AI-assisted drug discovery software” as a regulated medical device, requiring clinical validation. However, the guidelines also provide a fast-track pathway for AI-discovered drugs targeting unmet medical needs (rare diseases, antimicrobial resistance).
- WHO’s Global Strategy on Digital Health 2025-2030: Includes AI for biotechnology as a priority area, with $50M allocated for low- and middle-income country capacity building (genomics AI, infectious disease diagnostics).
Competitive Landscape: Key Suppliers
The AI in Biotechnology market features a mix of pure-play AI biotech companies, large pharma-backed platforms, and technology giants:
| Tier | Vendors | Focus Area |
|---|---|---|
| Pure-Play AI Biotech | Recursion Pharmaceuticals, Exscientia, XtalPi, Schrödinger, Owkin, Evogene, BioNTech (AI unit), MedySapiens | Drug discovery, diagnostics, target identification |
| Pharma-Backed Platforms | Bayer-Leaps (partnerships with Recursion), Sanofi-Exscientia, Amgen-Owkin, Roche-Genentech (internal AI) | Collaborative drug discovery, risk-sharing models |
| Technology Giants (Biotech Focus) | Google DeepMind (AlphaFold), Microsoft (BioGPT), NVIDIA (Clara Discovery, BioNeMo) | Foundational models, computational platforms, hardware |
Other notable players: None identified beyond the listed vendors – a fragmented market with pure-play AI biotech companies holding an estimated 45% share, pharma-backed platforms 30%, and technology giants 25% (per QYResearch 2024 vendor analysis).
Original Analyst Perspective (30-Year Industry Lens)
Having tracked drug discovery R&D, computational biology, and biotech innovation across five continents, I observe three under-discussed trends:
- The Pharma-AI Biotech Partnership Model Maturation: Early-stage AI biotech companies (Recursion, Exscientia, XtalPi) have shifted from “we will replace pharma R&D” to “we accelerate specific steps in the pipeline.” The dominant business model is now risk-sharing partnerships – AI biotech receives upfront payment ($20-50M), milestone payments ($100-500M upon successful Phase II/III), and tiered royalties (5-15% of net sales). In 2025 alone, 27 such partnerships were announced, totaling $8.2B in potential milestone payments (per Evaluate Pharma). Investors should monitor partnership terms – large upfront payments signal high confidence, while milestone-heavy structures indicate higher risk but greater upside.
- Drug Development vs. Diagnostics Divergence:
- Drug development (discovery through clinical trials) has a longer ROI horizon (5-10 years) but higher potential returns (blockbuster drugs >$1B annually). AI’s impact here is measured by reduced failure rates – a 10% reduction in Phase II failures saves the industry an estimated $5B annually. Pure-play AI biotech companies (Recursion, Exscientia) are valued on pipeline progress (number of molecules in clinical trials, partnership milestone achievements).
- Diagnostics (AI-powered imaging, genomics, liquid biopsy) has a shorter ROI horizon (2-4 years) but faces reimbursement hurdles (FDA/EMA approval, payer coverage decisions). Companies like Owkin and MedySapiens are valued on clinical validation studies (sensitivity, specificity, AUC) and adoption by health systems.
- The Generative AI Protein Design Gold Rush: Since AlphaFold 3’s release (May 2025), the barrier to entry for computational protein design has collapsed. Over 50 startups have emerged, offering generative design of novel enzymes, antibodies, and peptides. However, experimental validation remains the bottleneck – synthesizing and testing 10,000 AI-designed proteins costs $1-2M and takes 3-6 months. QYResearch’s full report predicts consolidation by 2028, with 5-10 platforms surviving (those with automated wet labs, high-throughput validation, and pharma partnerships).
Strategic Recommendations for Decision Makers
For Biotech R&D & CSOs:
- Prioritize generative AI for lead optimization – molecules designed with generative models have 30-40% higher predicted binding affinity and 50% lower toxicity signals (preclinical data, 2025). Integrate AI platforms (XtalPi, Schrödinger) early in discovery, not as an afterthought.
- Invest in federated learning for multi-institutional collaborations – the Owkin model (15 European cancer centers) demonstrates that data silos can be overcome without compromising patient privacy or IP.
For Pharma Business Development & Licensing Executives:
- Structure risk-sharing partnerships with AI biotech companies – upfront payments ($10-30M) for target discovery, milestone payments ($50-200M) for IND filing/Phase I completion, and royalties (5-10%). Avoid “service provider” models (fee-for-service) – they align incentives poorly.
- For diagnostics AI , prioritize FDA Breakthrough Device designation or EU Class III certification – these are prerequisites for reimbursement in major markets.
For Investors:
- Monitor pipeline progress (number of molecules in clinical trials, milestone achievements) for pure-play AI biotech – this is the primary value driver. Exscientia (8 molecules in clinical trials) vs. Recursion (6 molecules) – both have similar market caps ($1.5-2.0B), but Exscientia’s partnership with Sanofi (up to $5.2B in milestones) suggests greater upside.
- Watch for FDA/EMA regulatory decisions on AI-discovered molecules – approval of Recursion’s REC-994 (expected Q3 2026) would be a major catalyst for the entire sector, validating AI’s ability to produce safe, effective drugs.
- Assess data moats – companies with proprietary, high-quality biological datasets (e.g., Recursion’s 5 petabytes of cellular imaging data, BioNTech’s patient-derived tumor samples) have sustainable competitive advantages over those relying on public data (e.g., Protein Data Bank).
Conclusion & Next Steps
The AI in Biotechnology market is at an inflection point: generative AI for protein design, federated learning for data sharing, and regulatory clarity (EU AI Act, FDA EDSTP) are accelerating adoption across drug development and diagnostics. QYResearch’s full report provides 150+ data tables, vendor market shares by technology type (ML/DL, NLP, others), 5-year regional forecasts (North America, Europe, Asia-Pacific, RoW), and case studies from 25 AI-discovered molecules in clinical trials.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
